COVID-19’da Sitokin Salınım Sendromu ve Tedavi Yaklaşımları

Yeni ortaya çıkan coronavirus hastalığı 2019 (COVID-19) küresel bir sağlık sorunudur ve pandemi olarak kabul edilmiştir. COVID-19, hastaların çoğunda hafif grip benzeri semptomlara yol açmasına rağmen, hastalık akut solunum sıkıntısı sendromu ve sitokin salınım sendromu gibi sıklıkla ölümcül, ciddi komplikasyonlara neden olabilir. Bu hastalarda lenfositik sitolitik aktivitedeki defektler proinflamatuar sitokin kaskadını tetiklemekte ve “sitokin fırtınasını” başlatmaktadır. Sonuç olarak, dokulara kontrolsüz aktif makrofaj girişine ve hemofagositoza yol açmaktadır. Burada, COVID-19’da konakçı hücrelerin yanıtları, sitokin salınım sendromu ve sitokin fırtınasını durdurmak için tedavi yaklaşımları ele alınmıştır.

Cytokine Release Syndrome and Treatment in COVID-19

The emergent outbreak of coronavirus disease 2019 (COVID-19) is a global health problem and has been recognizedas a pandemic. Although COVID-19 leads to mild flu-like symptoms in most patients, the disease may cause frequentlyfatal, severe complications, such as acute respiratory distress syndrome and cytokine release syndrome. In these patients, defects in lymphocytic cytolytic activity trigger the proinflammatory cytokine cascade, and then “cytokine storm”begins. As a result, it leads to uncontrolled active macrophage entry into the tissues and hemophagocytosis. Here, theresponses of host cells, cytokine release syndrome and the therapeutic approaches to alleviate the cytokine storm inCOVID-19 will be reviewed.

PDF

___

1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565–74.
2. Nazinitsky A, Rosenthal KS. Cytokine storms: systemic disasters of infectious diseases. Infect Dis Clin Pract 2010;18:188–92.
3. Behrens EM. Cytokines in cytokine storm syndrome. In: Cron RQ, Behrens EM. Cytokine Storm Syndrome. Cham: Springer International Publishing 2019;197–207.
4. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 2020; doi: 10.1101/2020.02.12.945576.
5. Maclean OA, Orton R, Singer J, Robertson DL. Response to “On the origin and continuing evolution of SARS-CoV-2”. 2020. http:// virological.org/t/response-to-on-the-origin-and-continuingevolution-of-sars-cov-2/418 (accessed March 7, 2020)
6. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2.
7. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017;39:529–39.
8. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv 2020; doi: 10.1101/2020.03.01.20029769.
9. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
10. 10. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-9.
11. Yu L, Tong Y, Shen G, Fu A, Lai Y, Zhou X, et al. Immunodepletion with hypoxemia: a potential high risk subtype of coronavirus disease 2019. medRxiv 2020; doi: 10.1101/2020. 03.03.20030650.
12. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2.
13. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
14. Chen L, Liu HG., Liu W, Liu J, Liu K, Shang J. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi.2020;43:E005. doi: 10.3760/ cma.j.issn.1001-0939.2020.0005.
15. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv 2020; doi: 10.1101/2020.02.16.20023671.
16. Okabayashi T, Kariwa H, Yokota S, Iki S, Indoh T, Yokosawa N, et al. Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections. J Med Virol 2006;78:417–24.
17. Ling W. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020 doi 10.1016/j.medmal.2020.03.007.
18. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G. A trial of lopinavirritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382:1787-99.
19. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020;395:683-4.
20. Zha L. Impact of corticosteroid treatment in patients with coronavirus disease 2019. Med J Aust 2020 March 9.
21. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar 13; ;e200994 doi: 10.1001/ jamainternmed.2020.0994.
22. Editor(s): Wei, Pei-Fang;National Health Commission, National Administration of Traditional Chinese Medicine Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7) Chin Med J 2020;133:pp1087-95.
23. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–3.
24. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20; ;105949. doi: 10.1016/j. ijantimicag.2020.105949.
25. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020 Mar;55:105938. doi: 10.1016/j.ijantimicag.2020.105938.
26. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155-66.
27. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:033–4.
28. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846-8.
29. Herold T, Jurinovic V, Arnreich C, Hellmuth JC, von BergweltBaildon M, Klein M, et al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. medRxiv 2020. In press, https://doi.org/10. 1101/2020.04.01.20047381. Accessed April 8, 2020.
30. Xu L, Mao Y, Chen G. Risk factors for severe corona virus disease 2019 (COVID-19) patients: a systematic review and meta analysis. medRxiv 2020:2020.03.30.20047415 doi 10.1101/2020.03.30.20047415.
31. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 2016;8:959– 70.
32. Xu XL, Han MF, Li TT, Sun W, Wang DS, Fu BQ, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv 202003.00026.
33. Kawada J, Kitagawa Y, Iwata N, Ito Y. Clinical characteristics of influenza virus infection in juvenile idiopathic arthritis patients treated with tocilizumab. Mod Rheumatol 2013;23:972–6.
34. Rutherford AI, Subessinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2018;77:905–10.
35. Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun 2020;17:102468. doi: 10.1016/j. jaut.2020.102468.
36. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 2020; doi: 10.1101/2020.02.12.945576
37. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of antiinflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol 2020;214:108393 doi 10.1016/j.clim.2020.108393.
38. Zhou G, Chen S, Chen Z. Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies. Front Med 2000;14:117-25.